Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
F. Stephen Hodi(Dana-Farber Cancer Institute), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), René González(University of Colorado Denver), Jean-Jacques Grob(Aix-Marseille Université), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), C. Lance Cowey(Texas Oncology), Christopher D. Lao(University of Michigan), Dirk Schadendorf(University of Duisburg-Essen), John Wagstaff(Swansea University), Reinhard Dummer(See-Spital), Pier Francesco Ferrucci(European Institute of Oncology), Michael Smylie, Andrew Hill(Trans Tasman Radiation Oncology Group), David Hogg(Princess Margaret Cancer Centre), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Joel Jiang(Bristol-Myers Squibb (United States)), Jasmine I. Rizzo(Bristol-Myers Squibb (United States)), James Larkin(Royal Marsden NHS Foundation Trust), Jedd D. Wolchok(Cornell University)
Cited by 1,403
Abstract
Related Papers
No related papers found
Powered by citation graph analysis